Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sanyou Biopharmaceuticals Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners within 1 distinct art unit, so the technical setting is shared while examiner handling is divided.
JOHANSEN, PETER N. is the busiest examiner, with 1 pending action. Counsel can track examiner-specific requirements while using the common art-unit context to support consistent prosecution positions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702388 | Anti-CD47/Anti-CLDN18.2 Bispecific Antibody and Use Thereof | JOHANSEN, PETER N. | — |
| 18558534 | ANTI-CD40 ANTIBODY AND USE THEREOF | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702388 | Anti-CD47/Anti-CLDN18.2 Bispecific Antibody and Use Thereof | JOHANSEN, PETER N. | — | §112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18558534 | ANTI-CD40 ANTIBODY AND USE THEREOF | BORGEEST, CHRISTINA M | 1675 | DP | Final Rejection | — | Pending | Nov 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSanyou Biopharmaceuticals Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Peter N. Johansen has the most, with 1 of Sanyou Biopharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
